Now showing items 1-3 of 3
Prostate specific membrane antigen and DNA damage repair in advanced prostate cancer
(Institute of Cancer Research (University Of London), 2022-03-31)
Identification and implementation of novel therapeutic strategies for advanced prostate cancer (PCa) remains an urgent, unmet clinical need. Prostate Specific Membrane Antigen (PSMA), a PCa biomarker, is currently being ...
Biomarkers of therapy response and resistance in clear cell renal cell carcinoma AND Adaptive immune response to SARS-CoV-2 and COVID-19 vaccines in cancer patients
(Institute of Cancer Research (University Of London), 2022-04-30)
The cornerstone of treatment for metastatic clear cell renal cell carcinoma (ccRCC) are anti-VEGF and/or immune checkpoint inhibitors (CPI). However, there are no clinically implemented predictive biomarkers in any therapeutic ...
Identifying predictive and prognostic markers in localised oesophagogastric cancer
(Institute of Cancer Research (University Of London), 2022-11-23)
The survival of patients with localised oesophagogastric (OG) cancer is poor even with multimodality therapy and modern surgical techniques. The need to identify robust but easily-reproducible prognostic and predictive ...